Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Share-based Compensation: 2011-2025

Historic Share-based Compensation for Fennec Pharmaceuticals (FENC) over the last 13 years, with Sep 2025 value amounting to $2.2 million.

  • Fennec Pharmaceuticals' Share-based Compensation rose 21.86% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.6 million, marking a year-over-year increase of 17.54%. This contributed to the annual value of $5.1 million for FY2024, which is 5.47% down from last year.
  • Latest data reveals that Fennec Pharmaceuticals reported Share-based Compensation of $2.2 million as of Q3 2025, which was up 48.53% from $1.5 million recorded in Q2 2025.
  • In the past 5 years, Fennec Pharmaceuticals' Share-based Compensation ranged from a high of $2.5 million in Q2 2023 and a low of $399,000 during Q1 2022.
  • In the last 3 years, Fennec Pharmaceuticals' Share-based Compensation had a median value of $1.1 million in 2024 and averaged $1.4 million.
  • In the last 5 years, Fennec Pharmaceuticals' Share-based Compensation skyrocketed by 172.93% in 2023 and then plummeted by 63.63% in 2024.
  • Fennec Pharmaceuticals' Share-based Compensation (Quarterly) stood at $917,000 in 2021, then tumbled by 32.03% to $827,000 in 2022, then grew by 3.63% to $857,000 in 2023, then skyrocketed by 31.16% to $1.1 million in 2024, then increased by 21.86% to $2.2 million in 2025.
  • Its Share-based Compensation stands at $2.2 million for Q3 2025, versus $1.5 million for Q2 2025 and $798,000 for Q1 2025.